enGene Holdings Inc. (NASDAQ:ENGNW) Sees Significant Decrease in Short Interest

enGene Holdings Inc. (NASDAQ:ENGNW) saw a significant decrease in short interest in March. As of March 13th, there was short interest totaling 3,741 shares, a decrease of 51.5% from the February 26th total of 7,709 shares. Based on an average daily volume of 2,988 shares, the short-interest ratio is presently 1.3 days.

enGene Stock Performance

Shares of NASDAQ ENGNW remained flat at $2.31 during trading on Thursday. The stock had a trading volume of 4,000 shares, compared to its average volume of 18,761. enGene has a twelve month low of $0.51 and a twelve month high of $4.20. The stock has a fifty day moving average price of $3.02 and a 200-day moving average price of $2.39.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.